CCT301-38

BIOLOGICAL2 trials

Sponsors

Shanghai PerHum Therapeutics Co., Ltd.

Conditions

Renal Cell CarcinomaSAR

Phase 1

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma

TerminatedNCT03393936

Shanghai PerHum Therapeutics Co., Ltd.Renal Cell Carcinoma

Start: 2018-03-26End: 2023-06-30Updated: 2024-10-28

CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas

TerminatedNCT05128786

Shanghai PerHum Therapeutics Co., Ltd.SAR

Start: 2021-12-30End: 2024-10-24Updated: 2024-10-28

Related Papers

Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.

2023-04-086 citations